TZAR
LABS
UK

Tzar Labs UK
has opened in London

Tzar Labs have opened their laboratory in London, joining the Singapore and Indian facilities. The HrC Genomics cancer screening test and the BCube Tests for cancer, diabetes, cardiovascular disease, and neurodegenerative disease are now available.

Please contact Steve Smith with any inquiries on 020 8050 2578 or contact.uk@tzarlabs.com

The HrC Genomics Test

The HrC Genomics test is a breakthrough blood test which evaluates the expression levels of rare stem cell markers which may be indicative of cancer. Capable of detecting all cancer types in a single blood test, it has a sensitivity/accuracy of 90% plus, including at Stage One. The HrC Genomics test provides an indication of the likelihood of the presence or absence of cancer. It has won the 2025 Edison Gold Award for Innovation.

The BCube Tests

The B-Cube Tests are geno-molecular analyses that use transcriptome based NGS data focused on that are linked to a particular condition-cancer diabetes cardiovascular condition and neurological condition markers and genetic pathways. A comprehensive report (approximately 20-30 pages) is provided, with an optional Orthomolecular and Pharmacotranscriptomic Report available for clinicians, detailing possible intervention options. A clinician may use this report in conjunction with other “standard of care” tests.

The BCube Tests currently available are:

• BCube Onco

BCube Onco is a BCube test focusing on cancer, providing more detailed information than the HrC screening test. This test can be used by cancer survivors to monitor recurrence and/or remission, and also by active cancer patients to monitor treatment efficacy.

• BCube Diabetes

This test evaluates the risk and management of diabetes, including Type 1, Type 2, and pre-diabetes. Clinicians may use it alongside standard of care tests such as HbA1c, Fasting glucose, oral glucose tolerance tests, insulin test, and C-peptide measurements to tailor personalised interventions. The insights help optimise lifestyle changes, medication adjustments, and monitoring strategies for better blood sugar control and reduced complications. It also supports risk assessment for healthy individuals.

• BCube Cardiac

This test evaluates the risk of and status of cardiovascular diseases, including coronary artery disease, heart failure, and arrhythmias. The result can help guide personalised treatment plans and preventative measures to support heart health.

• BCube Neuro

This test evaluates the risk/status of neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's Disease. The results can assist in early diagnosis monitoring disease progression, and tailoring treatment strategies to improve patient outcomes and quality of life.